Skip to main content
Top
Published in: Indian Journal of Gastroenterology 4/2014

01-07-2014 | Original Article

A multicenter prospective study of infections related morbidity and mortality in cirrhosis of liver

Authors: Rajiv Baijal, Deepak Amarapurkar, H. R. Praveen Kumar, Sandeep Kulkarni, Nimish Shah, Soham Doshi, Deepak Gupta, Mayank Jain, Nikhil Patel, Praful Kamani, S. K. Issar, Mrudul Dharod, Apoorva Shah, Madhuri Chandnani, Sonali Gautam

Published in: Indian Journal of Gastroenterology | Issue 4/2014

Login to get access

Abstract

Background and Aims

Infections are a common and serious complication among patients with cirrhosis. We assessed the epidemiology, risk factors, and clinical consequences of bacterial infections in cirrhotic patients.

Methods

In this multicenter prospective study, all patients with cirrhosis of liver with different infections were analyzed. Infections were classified as community-acquired (CA), healthcare-associated (HCA), or hospital-acquired (HA). Site of infection and characteristics of bacteria were recorded; effect on liver function and 30-day survival were evaluated.

Results

One hundred and six out of 420 (25 %) patients with cirrhosis of liver had infection. Infection rate among indoor patients was 37.5 % (92/245) and among outdoor patients was 8 % (14/175). Out of 106 patients, CA, HCA, and HA were seen in 19.8 %, 50 %, and 30.2 %, respectively. Spontaneous bacterial peritonitis (31.1 %), urinary tract infections (22.6 %), and pneumonia and cellulitis (11.3 % each) were common infections. Gram-negative bacteria (54 %) were more common than Gram-positive cocci (46 %). Multidrug resistant (MDR) organisms were seen in 41.7 % of patients. Most of the MDR organisms were seen in HCA and HA patients. The degree of liver impairment was significantly more severe in patients with infection. Independent predictor of infection was high Child-Turcott-Pugh (CTP) class (p = 0.006, Child B vs. A (odds ratio (OR) 3.04 95 % CI = 1.63 to 5.68) and Child C vs. A (OR 4.17 95 % CI = 2.12 to 8.19). Overall in-hospital mortality was 7.6 %. Patients with infection had increased mortality at 30-day follow up compared to those without infection (23.5 % vs. 2.2 %; p<0.001).

Conclusions

Infections are one of the important causes of morbidity and mortality in patients with cirrhosis of liver. The most frequent infections are HCA and HA. Infection predisposes to deterioration of liver function and increases mortality. Cirrhotic patients should be monitored closely for infections especially those with Child class B and C.
Literature
1.
go back to reference Bajaj JS, O'Leary JG, Wong FK, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut. 2012;61:1219–25.PubMedCentralPubMedCrossRef Bajaj JS, O'Leary JG, Wong FK, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut. 2012;61:1219–25.PubMedCentralPubMedCrossRef
3.
go back to reference Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18:353–8.PubMedCrossRef Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18:353–8.PubMedCrossRef
4.
go back to reference Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246–56.PubMedCrossRef Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246–56.PubMedCrossRef
5.
go back to reference Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–8.PubMedCrossRef Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–8.PubMedCrossRef
6.
go back to reference Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for HCA bacterial infections. Clin Gastroenterol Hepatol. 2010;8:979–85.PubMedCrossRef Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for HCA bacterial infections. Clin Gastroenterol Hepatol. 2010;8:979–85.PubMedCrossRef
7.
go back to reference Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–61.PubMedCrossRef Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–61.PubMedCrossRef
8.
go back to reference Campillo B, Dupeyron C, Richardet JP, Mangeney N, Georges L. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clini Infect Dis. 1998;26:1066–70.CrossRef Campillo B, Dupeyron C, Richardet JP, Mangeney N, Georges L. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clini Infect Dis. 1998;26:1066–70.CrossRef
9.
go back to reference Bajaj JS, O’Leary JG, Reddy KR, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56:2328–35.PubMedCentralPubMedCrossRef Bajaj JS, O’Leary JG, Reddy KR, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56:2328–35.PubMedCentralPubMedCrossRef
10.
go back to reference Jain AK, Sircar S, Jain M, Adkar S, Waghmare C, Chahwala F. Acute febrile illness in cirrhosis—thinking beyond spontaneous bacterial peritonitis. Trop Doct. 2012;42:200–2.PubMed Jain AK, Sircar S, Jain M, Adkar S, Waghmare C, Chahwala F. Acute febrile illness in cirrhosis—thinking beyond spontaneous bacterial peritonitis. Trop Doct. 2012;42:200–2.PubMed
11.
go back to reference Mohan P, Ramu B, Bhaskar E, Venkataraman J. Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis. Ann Hepatol. 2011;10:15–20.PubMed Mohan P, Ramu B, Bhaskar E, Venkataraman J. Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis. Ann Hepatol. 2011;10:15–20.PubMed
12.
go back to reference Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.PubMedCrossRef Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.PubMedCrossRef
13.
go back to reference Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.PubMedCrossRef Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.PubMedCrossRef
14.
go back to reference Guarner C, Soriano G. Spontaneous bacterial peritonitis. Sem Liver Dis. 1997;17:203–17.CrossRef Guarner C, Soriano G. Spontaneous bacterial peritonitis. Sem Liver Dis. 1997;17:203–17.CrossRef
15.
go back to reference Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology. 1988;95:1351–5.PubMed Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology. 1988;95:1351–5.PubMed
16.
go back to reference Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–18.PubMedCentralPubMed Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–18.PubMedCentralPubMed
17.
go back to reference Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72:573–83.PubMed Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72:573–83.PubMed
18.
go back to reference Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269–82.PubMedCentralPubMedCrossRef Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269–82.PubMedCentralPubMedCrossRef
19.
go back to reference Lo GH, Lai KH, Shen MT, Chang CF. A comparison of the incidence of transient bacteremia and infectious sequelae after sclerotherapy and rubber band ligation of bleeding esophageal varices. Gastrointest Endosc. 1994;40:675–9.PubMed Lo GH, Lai KH, Shen MT, Chang CF. A comparison of the incidence of transient bacteremia and infectious sequelae after sclerotherapy and rubber band ligation of bleeding esophageal varices. Gastrointest Endosc. 1994;40:675–9.PubMed
20.
go back to reference Rimola A, Navasa M. Infections in liver disease. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, (eds). Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford: Oxford University Press; 1999. pp.1861–74. Rimola A, Navasa M. Infections in liver disease. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, (eds). Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford: Oxford University Press; 1999. pp.1861–74.
21.
go back to reference Llach J, Elizalde JI, Bordas JM, et al. Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing lower intestinal endoscopy. Gastrointest Endosc. 1999;49:214–17.PubMedCrossRef Llach J, Elizalde JI, Bordas JM, et al. Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing lower intestinal endoscopy. Gastrointest Endosc. 1999;49:214–17.PubMedCrossRef
22.
go back to reference Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, (eds). Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995. pp. 662–90. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, (eds). Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995. pp. 662–90.
23.
go back to reference Friedman ND, Kaye KS, Stout JE, et al. Health care associated bloodstream infections in adults: a reason to change the accepted definition of CA infections. Ann Intern Med. 2002;137:791–7.PubMedCrossRef Friedman ND, Kaye KS, Stout JE, et al. Health care associated bloodstream infections in adults: a reason to change the accepted definition of CA infections. Ann Intern Med. 2002;137:791–7.PubMedCrossRef
24.
go back to reference Valenti WM, Chiarello LA. Overview of hospital infection control and nosocomial infections. In: Resse RE, Douglas RG Jr, (eds). A Practical Approach to Infectious Diseases. Boston, MA: Lippincott; 1986. pp. 545–55. Valenti WM, Chiarello LA. Overview of hospital infection control and nosocomial infections. In: Resse RE, Douglas RG Jr, (eds). A Practical Approach to Infectious Diseases. Boston, MA: Lippincott; 1986. pp. 545–55.
25.
go back to reference Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.PubMedCrossRef Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.PubMedCrossRef
26.
go back to reference Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acineto-bacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55:1619–29.PubMedCrossRef Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acineto-bacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55:1619–29.PubMedCrossRef
27.
go back to reference Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63:353–65.PubMedCrossRef Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63:353–65.PubMedCrossRef
28.
go back to reference Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45:223–9.PubMedCrossRef Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45:223–9.PubMedCrossRef
29.
go back to reference Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009;50:2022–33.PubMedCrossRef Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009;50:2022–33.PubMedCrossRef
30.
go back to reference Garcia Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol. 2004;18:353–72.PubMedCrossRef Garcia Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol. 2004;18:353–72.PubMedCrossRef
32.
go back to reference Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27:1207–12.PubMedCrossRef Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27:1207–12.PubMedCrossRef
33.
go back to reference Rongey C, Lim NH, Runyon BA. Cellulitis in patients with cirrhosis and edema: an under-recognized complication currently more common that spontaneous bacterial peritonitis. Open Gastro J. 2008;2:24–7.CrossRef Rongey C, Lim NH, Runyon BA. Cellulitis in patients with cirrhosis and edema: an under-recognized complication currently more common that spontaneous bacterial peritonitis. Open Gastro J. 2008;2:24–7.CrossRef
34.
go back to reference Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2012;49:2087–107.CrossRef Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2012;49:2087–107.CrossRef
35.
go back to reference Perez PM, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31:43–8.CrossRef Perez PM, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31:43–8.CrossRef
36.
go back to reference Reiberger T, Ferlitsch A, Payer BA, et al. Nonselective beta-blocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2012;58:911–21.PubMedCrossRef Reiberger T, Ferlitsch A, Payer BA, et al. Nonselective beta-blocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2012;58:911–21.PubMedCrossRef
37.
go back to reference Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38:407–14.PubMedCrossRef Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38:407–14.PubMedCrossRef
38.
go back to reference Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012;36:866–74.PubMedCentralPubMedCrossRef Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012;36:866–74.PubMedCentralPubMedCrossRef
39.
go back to reference Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26–42.PubMedCrossRef Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26–42.PubMedCrossRef
40.
go back to reference Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity andmortality in cirrhosis. Am J Gastroenterol. 2007;102:1510–17.PubMedCrossRef Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity andmortality in cirrhosis. Am J Gastroenterol. 2007;102:1510–17.PubMedCrossRef
41.
go back to reference Jun DW, Kim KT, Lee OY, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci. 2010;55:1465–71.PubMedCrossRef Jun DW, Kim KT, Lee OY, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci. 2010;55:1465–71.PubMedCrossRef
Metadata
Title
A multicenter prospective study of infections related morbidity and mortality in cirrhosis of liver
Authors
Rajiv Baijal
Deepak Amarapurkar
H. R. Praveen Kumar
Sandeep Kulkarni
Nimish Shah
Soham Doshi
Deepak Gupta
Mayank Jain
Nikhil Patel
Praful Kamani
S. K. Issar
Mrudul Dharod
Apoorva Shah
Madhuri Chandnani
Sonali Gautam
Publication date
01-07-2014
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 4/2014
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-014-0461-3

Other articles of this Issue 4/2014

Indian Journal of Gastroenterology 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.